全球抗真菌药物市场规模、份额、趋势和成长分析报告（2026-2034年）

预计抗真菌药物市场将从 2025 年的 216.7 亿美元成长到 2034 年的 310.9 亿美元，2026 年至 2034 年的复合年增长率为 4.09%。

随着全球真菌感染疾病发病率的不断上升，全球抗真菌药物市场也稳步成长。抗真菌药物用于治疗影响皮肤、指甲、肺部和身体其他部位的真菌感染疾病。这些药物在治疗念珠菌症、曲菌症和其他真菌性疾病方面发挥着至关重要的作用。

市场成长主要受免疫力受损患者数量增加的推动，这些患者更容易感染疾病真菌。接受化疗、器官移植或长期抗生素治疗的患者通常需要抗真菌药物治疗。人们对真菌感染疾病的认识不断提高以及诊断能力的进步也促进了抗真菌药物需求的增长。

抗真菌药物市场前景依然光明，主要得益于药物研发不断推进，促使更有效的治疗方法不断涌现。製剂的改进和联合治疗的进步有望提升治疗效果并降低抗药性。医疗保健覆盖范围的扩大和感染控制措施的加强也有望推动市场成长。随着全球医疗保健系统在应对感染疾病日益高效，抗真菌药物将继续发挥至关重要的作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球抗真菌药物市场：依药物类别划分

• 市场分析、洞察与预测
• Azole
• 棘白菌素类
• Polyenes
• Allylamines
• 其他药物类别

第五章 全球抗真菌药物市场：依适应症划分

• 市场分析、洞察与预测
• 皮肤丝状菌症
• 曲菌症
• 念珠菌症
• 白霉菌症
• 其他迹象

第六章 全球抗真菌药物市场：依感染疾病类型划分

• 市场分析、洞察与预测
• 全身性真菌感染疾病
• 表层抗真菌感染疾病

第七章 全球抗真菌药物市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 外用
• 注射药物

第八章 全球抗真菌药物市场：依药物分类

• 市场分析、洞察与预测
• 处方笺
• OTC

第九章 全球抗真菌药物市场：按类型划分

• 市场分析、洞察与预测
• 品牌商品
• 非专利的

第十章 全球抗真菌药物市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第十一章 全球抗真菌药物市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十二章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十三章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott Laboratories
  • Astellas Pharma Inc
  • Bayer AG
  • Enzon Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA

The Antifungal Drugs Market size is expected to reach USD 31.09 Billion in 2034 from USD 21.67 Billion (2025) growing at a CAGR of 4.09% during 2026-2034.

The global antifungal drugs market has grown steadily due to the increasing incidence of fungal infections worldwide. Antifungal drugs are used to treat infections caused by fungi that affect the skin, nails, lungs, and other parts of the body. These medications play an essential role in treating conditions such as candidiasis, aspergillosis, and other fungal diseases.

Market growth is driven by the rising number of patients with weakened immune systems who are more susceptible to fungal infections. Individuals undergoing chemotherapy, organ transplantation, or long-term antibiotic therapy often require antifungal treatments. Increasing awareness about fungal infections and improved diagnostic capabilities have also contributed to greater demand for antifungal medications.

The future outlook for the antifungal drugs market remains positive as pharmaceutical research continues to develop more effective treatment options. Advances in drug formulations and combination therapies may improve treatment outcomes and reduce resistance. Expanding healthcare access and improved infection control practices are expected to support market growth. As global healthcare systems address infectious diseases more effectively, antifungal drugs will remain an important therapeutic category.

MARKET SEGMENTATION

By Drug Class

• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Other Drug Classes

By Indication

• Dermatophytosis
• Aspergillosis
• Candidiasis
• Mucormycosis
• Other Indications

By Infection Type

• Systemic Antifungal Infections
• Superficial Antifungal Infections

By Route of Administration

• Oral
• Topical
• Injectable

By Medication

• Prescription
• OTC

By Type

• Branded
• Generic

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Abbott Laboratories, Astellas Pharma Inc, Bayer AG, Enzon Pharmaceuticals Inc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd, Merck Co Inc, Novartis AG, Pfizer Inc, Sanofi SA
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIFUNGAL DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Azoles Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Echinocandins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Polyenes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Allylamines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIFUNGAL DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Dermatophytosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Aspergillosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Candidiasis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Mucormycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIFUNGAL DRUGS MARKET: BY INFECTION TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Infection Type
• 6.2. Systemic Antifungal Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Superficial Antifungal Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIFUNGAL DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIFUNGAL DRUGS MARKET: BY MEDICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Medication
• 8.2. Prescription Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. OTC Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIFUNGAL DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Type
• 9.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ANTIFUNGAL DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Distribution Channel
• 10.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL ANTIFUNGAL DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 11.1. Regional Outlook
• 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.2.1 By Drug Class
  • 11.2.2 By Indication
  • 11.2.3 By Infection Type
  • 11.2.4 By Route Of Administration
  • 11.2.5 By Medication
  • 11.2.6 By Type
  • 11.2.7 By Distribution Channel
  • 11.2.8 United States
  • 11.2.9 Canada
  • 11.2.10 Mexico
• 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.3.1 By Drug Class
  • 11.3.2 By Indication
  • 11.3.3 By Infection Type
  • 11.3.4 By Route Of Administration
  • 11.3.5 By Medication
  • 11.3.6 By Type
  • 11.3.7 By Distribution Channel
  • 11.3.8 United Kingdom
  • 11.3.9 France
  • 11.3.10 Germany
  • 11.3.11 Italy
  • 11.3.12 Russia
  • 11.3.13 Rest Of Europe
• 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.4.1 By Drug Class
  • 11.4.2 By Indication
  • 11.4.3 By Infection Type
  • 11.4.4 By Route Of Administration
  • 11.4.5 By Medication
  • 11.4.6 By Type
  • 11.4.7 By Distribution Channel
  • 11.4.8 India
  • 11.4.9 Japan
  • 11.4.10 South Korea
  • 11.4.11 Australia
  • 11.4.12 South East Asia
  • 11.4.13 Rest Of Asia Pacific
• 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.5.1 By Drug Class
  • 11.5.2 By Indication
  • 11.5.3 By Infection Type
  • 11.5.4 By Route Of Administration
  • 11.5.5 By Medication
  • 11.5.6 By Type
  • 11.5.7 By Distribution Channel
  • 11.5.8 Brazil
  • 11.5.9 Argentina
  • 11.5.10 Peru
  • 11.5.11 Chile
  • 11.5.12 Rest of Latin America
• 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.6.1 By Drug Class
  • 11.6.2 By Indication
  • 11.6.3 By Infection Type
  • 11.6.4 By Route Of Administration
  • 11.6.5 By Medication
  • 11.6.6 By Type
  • 11.6.7 By Distribution Channel
  • 11.6.8 Saudi Arabia
  • 11.6.9 UAE
  • 11.6.10 Israel
  • 11.6.11 South Africa
  • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

• 12.1. Recent Developments
• 12.2. Company Categorization
• 12.3. Supply Chain & Channel Partners (based on availability)
• 12.4. Market Share & Positioning Analysis (based on availability)
• 12.5. Vendor Landscape (based on availability)
• 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL ANTIFUNGAL DRUGS INDUSTRY

• 13.1. Top Companies Market Share Analysis
• 13.2. Company Profiles
  • 13.2.1 Abbott Laboratories
  • 13.2.2 Astellas Pharma Inc
  • 13.2.3 Bayer AG
  • 13.2.4 Enzon Pharmaceuticals Inc
  • 13.2.5 GlaxoSmithKline Plc
  • 13.2.6 Glenmark Pharmaceuticals Ltd
  • 13.2.7 Merck & Co. Inc
  • 13.2.8 Novartis AG
  • 13.2.9 Pfizer Inc
  • 13.2.10 Sanofi S.A